Loading
institutionsInstitution
Cancer Center Clínica Universidad de Navarra / CIMA
The University of Navarra's cancer centre in Pamplona and Madrid, known for myeloma, immunotherapy research and one of Spain's first proton therapy units.
Also called: CCUNClínica Universidad de NavarraCIMA Universidad de Navarra
Overview
The Cancer Center Clínica Universidad de Navarra combines the university hospital's Pamplona and Madrid campuses with the CIMA research centre. Jesús San Miguel and Bruno Paiva have led international myeloma trials and developed next-generation flow cytometry for minimal residual disease, Ignacio Melero's laboratory is a reference in cancer immunotherapy and intratumoural immunostimulation, and Felipe Prósper's group works on cell therapy and gene therapy. The Madrid campus opened a proton therapy unit in 2020, among the first in Spain. The centre is OECI-accredited and offers early-phase trials, CAR-T and comprehensive genomic profiling to private and insured patients.
Location
Pamplona, ES
Type
cancer center · Universidad de Navarra
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#198 · 28 points (0 Newsweek + 0 NCI + 28 from 14 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to Clinica Universidad de Navarra, including child institutions. 775 works · 11,529 citations · 69% open access · 18% clinical trials · 1% reviews.
Oncology works per year
1732022
1822023
1482024
1472025
1252026
Most works
- Antonio González-Martı́n93 works
- Paula Rodríguez‐Otero79 works
- Ignacio Melero72 works
- Felipe Prósper46 works
- Jesús San Miguel42 works
- María‐Victoria Mateos39 works
- Miguel F. Sanmamed37 works
- Fernando Rotellar35 works
- Bradley J. Monk35 works
- Juan R. Rodríguez-Madoz34 works
Most cited
- Multiple myeloma and MRD
- Cancer immunotherapy (Melero)
- Proton therapy (Madrid)
- Cell and gene therapy
- CIMA research
Antonio González-Martín
Director, Cancer Center Clínica Universidad de Navarra
Medical oncologyOvarian cancerGynaecological oncology
Gynaecological medical oncologist directing the Cancer Center Clínica Universidad de Navarra; led the PRIMA trial of niraparib maintenance in ovarian cancer.
Bruno Sangro
Translational Research lead, Executive Committee
Hepatocellular carcinomaHepatologyLiver cancer immunotherapy
Hepatologist at Clínica Universidad de Navarra and a leading international investigator in liver cancer systemic therapy and radioembolisation.
Ignacio Melero
Professor of Immunology, Universidad de Navarra; Senior Consultant, Clínica Universidad de Navarra
Tumour immunologyIntratumoural immunotherapyCostimulatory agonists (CD137, OX40)
Spanish immunologist who pioneered CD137 agonist antibodies and intratumoural immunotherapy.
Jesús San Miguel
President, Internal Scientific Committee
Multiple myelomaHematologyMinimal residual disease
Hematologist who chairs the Cancer Center CUN internal scientific committee and is one of the most influential clinical investigators in multiple myeloma.
Similar pages
- InstitutionShandong Cancer Hospital and Institute
Shares Abscopal effect, Proton therapy, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- InstitutionSylvester Comprehensive Cancer Center, University of Miami
Shares Minimal / molecular residual disease (MRD), Proton therapy, MRD / molecular residual disease testing, Multiple myeloma.
- InstitutionIUCT Oncopole (Institut Universitaire du Cancer de Toulouse)
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, CAR-T cell therapy, Multiple myeloma.
- TrialCARTITUDE-4
Shares Jesús San Miguel, CAR-T cell therapy, Multiple myeloma.
- PairingPD-1 failure → TIL therapy
Shares TIL therapy, Melanoma, Immune checkpoint inhibitors.
- IdeactDNA-guided adjuvant therapy in stage II-III melanoma
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Melanoma, Immune checkpoint inhibitors.
- InstitutionNational Cancer Centre Singapore
Shares TIL therapy, Proton therapy, CAR-T cell therapy, Hepatocellular carcinoma.
- IdeaPlan the second CAR-T target before the first one is lost
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, CAR-T cell therapy, Multiple myeloma.